Evolving immunosuppressive regimens for lung transplant recipients.

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Allograft tolerance is crucial for graft survival in organ transplantation.
• Immunosuppression is the primary strategy to achieve and maintain graft function and tolerance.
• Lung transplant immunosuppression has evolved significantly, incorporating newer agents alongside foundational therapies.

Purpose of the Study:

• To review traditional and novel immunosuppressive agents used in lung transplantation.
• To describe a patient-centered approach to immunosuppression management post-lung transplant.
• To discuss current controversies in immunosuppression for lung transplant recipients.

Main Methods:

• Literature review of immunosuppressive therapies in lung transplantation.
• Analysis of pharmacological characteristics of immunosuppressive agents.
• Examination of patient-centered strategies and clinical controversies.

Main Results:

• Foundational immunosuppression includes calcineurin inhibitors, corticosteroids, and azathioprine.
• Expanding arsenal includes biological agents and targeted therapies for specific immune pathways.
• A patient-centered approach is essential for optimizing immunosuppression.

Conclusions:

• Immunosuppression in lung transplantation has evolved with a broader range of agents.
• Balancing efficacy, toxicity, and patient-specific needs is key in immunosuppressive therapy.
• Ongoing research and discussion are vital to address controversies in lung transplant immunosuppression.